The MCI-Park mice are compound mutant (Ndufs2fl/fl; DAT IREScre/+) animals in which Ndufs2, a gene encoding a core subunit of the mitochondrial respiratory chain, is selectively inactivated in ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

When Alois Alzheimer described the case of Auguste D. to an audience of fellow psychiatrists in Tuebingen, Germany, in 1906, what set her case apart was the fact that her dementia appeared before she ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

A potential treatment for Alzheimer’s disease relies on 40 Hz light or sound to entrain gamma rhythms in the brain. This intervention, pioneered by Li-Huei Tsai and colleagues at Massachusetts ...

Merck dropped a Valentine’s Day downer announcing they will stop the EPOCH trial of verubecestat in mild to moderate Alzheimer’s disease. A prespecified interim analysis by an external data-monitoring ...